Placebo News and Research

RSS

Study: Daily dietary supplementation with blend of omega fatty acids improves severe dry eye

Study findings published online, ahead of print, in Cornea show that daily dietary supplementation with a unique combination of omega fatty acids (GLA, EPA and DHA) for six months is effective in improving ocular irritation symptoms and halting the progression of inflammation that characterizes moderate to severe dry eye.

25 Jul 2013

NOXXON completes patient recruitment of NOX-E36 Phase IIa trial for treatment of diabetic nephropathy

NOXXON Pharma today announced the successful completion of patient recruitment of its NOX-E36 Phase IIa clinical trial for the treatment of diabetic nephropathy. NOX-E36 is a Spiegelmer® that binds and neutralizes CCL2/MCP-1 (C-C Chemokine Ligand / Monocyte Chemoattractant Protein-1), a pro-inflammatory chemokine that plays an important role in the progression of diabetic nephropathy, the most common single cause of chronic kidney failure and end-stage renal disease.

25 Jul 2013

Verastem's defactinib gets FDA orphan drug designation for treatment of mesothelioma

Verastem, Inc., focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced that lead cancer stem cell inhibitor, VS-6063 (defactinib), has received orphan drug designation from the U.S. Food and Drug Administration for use in the treatment of mesothelioma, a rare form of lung cancer.

24 Jul 2013

Study: Cannabis has no effect in slowing course of progressive multiple sclerosis

The first large non-commercial clinical study to investigate whether the main active constituent of cannabis (tetrahydrocannabinol or THC) is effective in slowing the course of progressive multiple sclerosis (MS), shows that there is no evidence to suggest this; although benefits were noted for those at the lower end of the disability scale.

24 Jul 2013

Prana Biotechnology completes PBT2 phase 2 trial in patients with Huntington's disease

Prana Biotechnology today announced the successful completion of Reach2HD, a phase 2 clinical trial in patients with early to mid-stage Huntington disease. The Company expects to announce the results arising from the trial in October.

23 Jul 2013

Array BioPharma announces positive results from ARRY-502 Phase 2 trial for allergic asthma

Array BioPharma Inc. today announced positive results from a placebo-controlled, randomized, double‑blind Phase 2 trial in mild to moderate persistent allergic asthma for ARRY-502, an oral CRTh2 antagonist.

23 Jul 2013

Imprimis to begin IRB-approved Impracor Phase III trial for acute pain associated with OA of the knee

Imprimis Pharmaceuticals, Inc., which is focused on the commercialization of compounded drug formulations utilizing the FDA 505(b)(2) development pathway, today announced it has received IRB approval for its Phase III clinical trial protocol of its lead product candidate, Impracor.

23 Jul 2013

BioCryst completes BCX4161 Phase 1 clinical trial for treatment of hereditary angioedema

BioCryst Pharmaceuticals, Inc. announced that the randomized, placebo-controlled, Phase 1 clinical trial of orally-administered BCX4161 in healthy volunteers successfully met all of its objectives.

22 Jul 2013

Resveratrol counteracts exercise benefits in older men

In older men, a natural antioxidant compound found in red grapes and other plants -- called resveratrol -- blocks many of the cardiovascular benefits of exercise, according to research published today [22 July 2013] in The Journal of Physiology.

22 Jul 2013

Boston Scientific initiates OPTIMISE trial to study ONS using Precision System for chronic migraine

Boston Scientific Corporation has launched a clinical trial to determine whether occipital nerve stimulation using the Precision System can safely and effectively treat chronic migraine when used in conjunction with anti-migraine medications.

20 Jul 2013

Biogen Idec announces acceptance of marketing applications for review of PLEGRIDY

Today Biogen Idec announced that U.S. and EU regulatory authorities have accepted the marketing applications for the review of PLEGRIDY (peginterferon beta-1a), the company's pegylated subcutaneous injectable candidate for relapsing forms of multiple sclerosis.

19 Jul 2013

Study supports topiramate as promising medication to treat addiction

The drug topiramate, typically used to treat epilepsy and more recently weight loss, may also help people addicted to both cocaine and alcohol use less cocaine, particularly heavy users, researchers in the department of Psychiatry at Penn Medicine report in a new study published in Drug and Alcohol Dependence.

19 Jul 2013

Computerized cognitive testing plays a key role in therapy development for dementia, AD

Computerized cognitive testing is increasingly playing a key role in therapy development for dementia and Alzheimer's disease. This week at the Alzheimer's Association International Conference, Keith Wesnes Ph.D., Practice Leader of Bracket and founder of the CDR System-, discussed new data for novel therapies at two poster presentations at the Alzheimer's Association International Conference.

19 Jul 2013

Study: Ultrasound waves applied to specific areas of brain appear to alter patients' moods

University of Arizona researchers have found in a recent study that ultrasound waves applied to specific areas of the brain appear able to alter patients' moods. The discovery has led the scientists to conduct further investigations with the hope that this technique could one day be used to treat conditions such as depression and anxiety.

19 Jul 2013

Oxytocin may not improve symptoms of children with autism, study finds

The so-called trust hormone, oxytocin, may not improve the symptoms of children with autism, a large study led by researchers at the University of New South Wales has found.

19 Jul 2013

Metabolomics tools predict who can benefit from treatment with certain antidepressants

Duke Medicine researchers have identified biochemical changes in people taking antidepressants - but only in those whose depression improves. These changes occur in a neurotransmitter pathway that is connected to the pineal gland, the part of the endocrine system that controls the sleep cycle, suggesting an added link between sleep, depression and treatment outcomes.

19 Jul 2013

Cubist initiates bevenopran Phase 3 studies in patients with chronic non-cancer pain and OIC

Cubist Pharmaceuticals, Inc. today announced the initiation of Phase 3 efficacy studies of bevenopran (previously known as CB-5945) in patients with chronic non-cancer pain and opioid-induced constipation.

19 Jul 2013

FDA approves Janssen Biotech's SIMPONI ARIATM for infusion for active rheumatoid arthritis

Janssen Biotech, Inc. announced today the U.S. Food and Drug Administration approval of SIMPONI ARIATM (golimumab) for infusion for the treatment of adults with moderately to severely active rheumatoid arthritis in combination with methotrexate.

19 Jul 2013

Celgene to discontinue treatment with REVLIMID in phase III ORIGIN trial

Celgene Corporation today announced that after consultation with the U.S. Food and Drug Administration Celgene will discontinue treatment with REVLIMID (lenalidomide) in the open-label, phase III ORIGIN trial, which enrolled 450 patients in over 100 sites in 26 countries.

18 Jul 2013

Adynxx receives FDA Fast Track designation for AYX1 Injection to treat chronic pain

Adynxx, a clinical-stage pharmaceutical company developing a first-in-class platform of therapeutics to address pain at its molecular roots, announced today that the U.S. Food and Drug Administration has granted Fast Track designation to AYX1 Injection for the prevention of chronic pain.

17 Jul 2013

Placebo News and Research

Study: Daily dietary supplementation with blend of omega fatty acids improves severe dry eye

NOXXON completes patient recruitment of NOX-E36 Phase IIa trial for treatment of diabetic nephropathy

Verastem's defactinib gets FDA orphan drug designation for treatment of mesothelioma

Study: Cannabis has no effect in slowing course of progressive multiple sclerosis

Prana Biotechnology completes PBT2 phase 2 trial in patients with Huntington's disease

Array BioPharma announces positive results from ARRY-502 Phase 2 trial for allergic asthma

Imprimis to begin IRB-approved Impracor Phase III trial for acute pain associated with OA of the knee

BioCryst completes BCX4161 Phase 1 clinical trial for treatment of hereditary angioedema

Resveratrol counteracts exercise benefits in older men

Boston Scientific initiates OPTIMISE trial to study ONS using Precision System for chronic migraine

Biogen Idec announces acceptance of marketing applications for review of PLEGRIDY

Study supports topiramate as promising medication to treat addiction

Computerized cognitive testing plays a key role in therapy development for dementia, AD

Study: Ultrasound waves applied to specific areas of brain appear to alter patients' moods

Oxytocin may not improve symptoms of children with autism, study finds

Metabolomics tools predict who can benefit from treatment with certain antidepressants

Cubist initiates bevenopran Phase 3 studies in patients with chronic non-cancer pain and OIC

FDA approves Janssen Biotech's SIMPONI ARIATM for infusion for active rheumatoid arthritis

Celgene to discontinue treatment with REVLIMID in phase III ORIGIN trial

Adynxx receives FDA Fast Track designation for AYX1 Injection to treat chronic pain

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News